Search

Your search keyword '"P. Brisou"' showing total 4 results
Start Over Author "P. Brisou" Publisher wiley
4 results on '"P. Brisou"'

1. S226: EFFICACY OF ANTI-PD1 THERAPY IN RELAPSED OR REFRACTORY EXTRANODAL NK/T CELL LYMPHOMA: A MATCHED COHORT ANALYSIS FROM THE LYSA

Author

Amira Marouf, Sammara Chaubard, Jean Marie Michot, Julien Rossignol, Camille Golfier, Olivier Allangba, Laure Philippe, Benoit Tessoulin, Adrien Chauchet, Bénédicte Deau, Lucie Oberic, Jacques Vargaftig, Aline Moignet, Aline Clavert, Rémy Duléry, Gabriel Brisou, Stéphanie Tardy, Virginie Fataccioli, Roch Houot, Rene Olivier Casasnovas, Catherine Thieblemont, Herve Ghesquieres, Sylvain Carras, Steven Le Gouill, Guillaume Cartron, Aurélien Marabelle, Olivier Tournilhac, Gandhi Laurent Damaj, Philippe Gaulard, Laurence De Leval, Francois Lemonnier, Emmanuel Bachy, Olivier Hermine, Lucile Couronné, and Arnaud Jaccard

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. S233: AXICABTAGENE CILOLEUCEL AS SECOND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF ALYCANTE, A PHASE 2 LYSA STUDY

Author

Roch Houot, Emmanuel Bachy, Guillaume Cartron, Francois-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Rémy Duléry, Catherine Thieblemont, Magalie Joris, Fabrice Jardin, Sylvain Choquet, Rene Olivier Casasnovas, Gabriel Brisou, Morgane Cheminant, Jacques Olivier Bay, Francisco Llamas, Cedric Menard, Karin Tarte, Marie-Helene Delfau-Larue, Emmanuel Itti, Clément Bailly, Yassine Al Tabaa, Camille Laurent, and Francois Lemonnier

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

4. Is the JAK2V617Fmutation detectable in healthy volunteers?

Author

Marie-Joelle Mozziconacci, P. Brisou, and Christophe Martinaud

Subjects
Adult, Male, medicine.medical_specialty, DNA Copy Number Variations, Biology, Polymerase Chain Reaction, Cohort Studies, Young Adult, Polycythemia vera, Gene Frequency, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Clinical significance, Young adult, Allele frequency, Aged, Aged, 80 and over, Myeloproliferative Disorders, Hematology, Essential thrombocythemia, food and beverages, Janus Kinase 2, Middle Aged, medicine.disease, Work-up, Amino Acid Substitution, Mutation, Mutation (genetic algorithm), Immunology, Female, France, Biomarkers
Abstract

The World Health Organization (WHO) has added detection of the JAK2 tyrosine kinase mutation, JAK2 V617F, in the diagnostic work up for myeloproliferative neoplasms (MPNs), especially for polycythemia vera (PV) and essential thrombocythemia (ET). The rational use of this new marker requires the determination of accurate thresholds of clinical significance and thus implies clarification of the presence or not of JAK2 V617F in healthy individuals. The aim of this study was to determine JAK2 V617F mutation levels in healthy subjects with no clinical or biological signs indicative of MPN. Results in 198 healthy subjects indicate that a very accurate quantification of JAK2 V617F is feasible when the analysis is performed with a highly sensitive and reliable RQ-PCR assay, and that the JAK2 V617F mutation may be detectable in very rare cases of healthy volunteers with no clinical symptoms of MPNs or blood disorder, but only at levels around the analytical threshold of the assay (0.035%) and far below the commonly accepted positivity cutoff (1%).

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results